Cargando…

Corrigendum: Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis

Detalles Bibliográficos
Autores principales:	Huang, Guirui, Huang, Shuaiyang, Cui, Hongsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802109/ https://www.ncbi.nlm.nih.gov/pubmed/36588674 http://dx.doi.org/10.3389/fphar.2022.1117317

Ejemplares similares

Effect of M6A regulators on diagnosis, subtype classification, prognosis and novel therapeutic target development of idiopathic pulmonary fibrosis
por: Huang, Guirui, et al.
Publicado: (2022)

The identification of metabolism-related subtypes and potential treatments for idiopathic pulmonary fibrosis
por: Yang, Changqing, et al.
Publicado: (2023)

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
por: Estornut, Cristina, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
por: Camelo, Ana, et al.
Publicado: (2014)

Small airway dysfunction in idiopathic pulmonary fibrosis
por: Yin, Chengsheng, et al.
Publicado: (2022)

A novel gene signature based on the hub genes of COVID-19 predicts the prognosis of idiopathic pulmonary fibrosis
por: Guo, Run, et al.
Publicado: (2022)

Heterogeneity in fibroblast proliferation and survival in idiopathic pulmonary fibrosis
por: Habiel, David M., et al.
Publicado: (2014)

Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023)

Exosomes in pathogenesis, diagnosis, and treatment of pulmonary fibrosis
por: Yang, Yang, et al.
Publicado: (2022)

Corrigendum: BI 1015550 is a PDE4B inhibitor and a clinical drug candidate for the oral treatment of idiopathic pulmonary fibrosis
por: Herrmann, Franziska Elena, et al.
Publicado: (2023)

Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021)

Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
por: Zhang, Tingwei, et al.
Publicado: (2022)

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis
por: Liu, Peipei, et al.
Publicado: (2021)

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022)

Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis
por: Wang, Rui, et al.
Publicado: (2022)

Engineering of Stimulus-Responsive Pirfenidone Liposomes for Pulmonary Delivery During Treatment of Idiopathic Pulmonary Fibrosis
por: Han, Meishan, et al.
Publicado: (2022)

Corrigendum: NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma
por: Huang, Zhen, et al.
Publicado: (2021)

Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution
por: Samarelli, Anna Valeria, et al.
Publicado: (2021)

Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication
por: Seeliger, Benjamin, et al.
Publicado: (2022)

Aberrant Expression of ACO1 in Vasculatures Parallels Progression of Idiopathic Pulmonary Fibrosis
por: Fukumoto, Jutaro, et al.
Publicado: (2022)

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies
por: Guo, Hehua, et al.
Publicado: (2023)

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis
por: Fujimoto, Hajime, et al.
Publicado: (2016)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model
por: Wu, Xuening, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 expression is not associated with an activated fibroblast phenotype in idiopathic pulmonary fibrosis
por: Kadefors, Måns, et al.
Publicado: (2022)

Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis
por: Li, Hui, et al.
Publicado: (2022)

Pharmacokinetics and tissue distribution of bleomycin-induced idiopathic pulmonary fibrosis rats treated with cryptotanshinone
por: He, Xiangjun, et al.
Publicado: (2023)

Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
por: Shen, Jiahui, et al.
Publicado: (2023)

Maimendong Decoction Improves Pulmonary Function in Rats With Idiopathic Pulmonary Fibrosis by Inhibiting Endoplasmic Reticulum Stress in AECIIs
por: Shen, Mengmeng, et al.
Publicado: (2020)

Corrigendum: Therapeutic potential of topical administration of acriflavine against hypoxia-inducible factors for corneal fibrosis
por: Zhu, Shuyan, et al.
Publicado: (2023)

Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis
por: Zhang, Jingcheng, et al.
Publicado: (2023)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis
por: Fernández Fabrellas, Estrella, et al.
Publicado: (2018)

Antifibrotic Mechanism of Cinobufagin in Bleomycin-Induced Pulmonary Fibrosis in Mice
por: Li, Xiaohe, et al.
Publicado: (2019)

Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis
por: Aburto, Myriam, et al.
Publicado: (2018)

Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone
por: Jiang, Chun-guo, et al.
Publicado: (2019)

Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis
por: Zhang, Yufeng, et al.
Publicado: (2020)

The Effect of Cardiovascular Medications on Disease-Related Outcomes in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis
por: Zhang, Wan-Tong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jhelg0f9jgeg6q3gd0189qkaj7